title: Hemostatic/fibrinolytic predictors of allograft coronary artery disease after cardiac transplantation.
abstract: Allograft coronary artery disease (CAD) remains the leading cause of morbidity and mortality affecting the long-term survival of patients after cardiac transplantation. Because there is increasing evidence that imbalances in hemostatic and fibrinolytic pathways are associated with graft failure, we hypothesized that atherothrombotic risk factors may contribute to allograft CAD. This study sought to determine if plasma hemostatic and fibrinolytic parameters are associated with the severity of allograft CAD. The extent of allograft CAD was investigated by angiography and intravascular ultrasound (IVUS) in 16 cardiac transplant recipients. Intimal thickening was quantified using IVUS by measuring the intimal index (li = intimal area/[intimal area + luminal area]) in two to five segments of the left anterior descending (LAD) coronary artery. The maximal li per patient was calculated and index to the time post-transplant (Mxli/Yr). Plasma fibrinogen (FGN), tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor-1 (PAI-1), lipoprotein(a) (Lp(a)), and net fibrinolytic activity of plasma were assayed 6-24 months after transplant as indicators of the fibrinolytic system and then correlated with the IVUS measurements. The FGN level correlated with the severity of intimal thickening, Mxli/Yr (r2 = 0.41, p = 0.008), and was inversely correlated with angiographic tertiary vessel filling (r2 = 0.25, p = 0.051). In patients with lower plasma fibrinolytic activity (lytic zone less than 100 mm2), Mxli/Yr was increased eightfold (0.218 +/- 0.137 versus 0.025 +/- 0.021, p = 0.001). t-PA (r2 = 0.0004, p = 0.94), PAI-1 (r2 = 0.008, p = 0.75) and Lp(a) levels (r2 = 0.11, p = 0.21) did not predict Mxli/Yr. Thus, we demonstrate that plasma FGN and net fibrinolytic activity correlate with the degree of intimal thickening measured by IVUS after cardiac transplantation. These data suggest that fibrin deposition may play a role in allograft CAD after cardiac transplantation.
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
authors.forename: C R
authors.initials: CR
authors.lastname: Meckel
authors.forename: T J
authors.initials: TJ
authors.lastname: Anderson
authors.forename: G H
authors.initials: GH
authors.lastname: Mudge
authors.forename: R N
authors.initials: RN
authors.lastname: Mitchell
authors.forename: A C
authors.initials: AC
authors.lastname: Yeung
authors.forename: A P
authors.initials: AP
authors.lastname: Selwyn
authors.forename: P
authors.initials: P
authors.lastname: Ganz
authors.forename: D I
authors.initials: DI
authors.lastname: Simon
mesh_terms: D000328:Adult; D001161:Arteriosclerosis / Q000209:etiology; D015415:Biomarkers; D017023:Coronary Angiography; D003327:Coronary Disease / Q000097:blood / Q000175:diagnosis / Q000209:etiology*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis; D016027:Heart Transplantation / Q000009:adverse effects* / Q000502:physiology*; D006487:Hemostasis; D006801:Humans; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D013927:Thrombosis / Q000209:etiology
chemical_list: D015415:Biomarkers; D005340:Fibrinogen